Blast shockwaves propagate Ca2+ activity via purinergic astrocyte networks in human central nervous system cells

In a recent study of the pathophysiology of mild, blast-induced traumatic brain injury (bTBI) the exposure of dissociated, central nervous system (CNS) cells to simulated blast resulted in propagating waves of elevated intracellular Ca 2+ . Here we show, in dissociated human CNS cultures, that these...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2016-05, Vol.6 (1), p.25713, Article 25713
Hauptverfasser: Ravin, Rea, Blank, Paul S., Busse, Brad, Ravin, Nitay, Vira, Shaleen, Bezrukov, Ludmila, Waters, Hang, Guerrero-Cazares, Hugo, Quinones-Hinojosa, Alfredo, Lee, Philip R., Fields, R. Douglas, Bezrukov, Sergey M., Zimmerberg, Joshua
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a recent study of the pathophysiology of mild, blast-induced traumatic brain injury (bTBI) the exposure of dissociated, central nervous system (CNS) cells to simulated blast resulted in propagating waves of elevated intracellular Ca 2+ . Here we show, in dissociated human CNS cultures, that these calcium waves primarily propagate through astrocyte-dependent, purinergic signaling pathways that are blocked by P2 antagonists. Human, compared to rat, astrocytes had an increased calcium response and prolonged calcium wave propagation kinetics, suggesting that in our model system rat CNS cells are less responsive to simulated blast. Furthermore, in response to simulated blast, human CNS cells have increased expressions of a reactive astrocyte marker, glial fibrillary acidic protein (GFAP) and a protease, matrix metallopeptidase 9 (MMP-9). The conjoint increased expression of GFAP and MMP-9 and a purinergic ATP (P2) receptor antagonist reduction in calcium response identifies both potential mechanisms for sustained changes in brain function following primary bTBI and therapeutic strategies targeting abnormal astrocyte activity.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep25713